CANF Can-Fite Biopharma Ltd Sponsore

-0.04  -1.67%
Previous Close 2.40
Open 2.42
Price To book 5.63
Market Cap 31.57M
Shares 13,379,000
Volume 24,524
Short Ratio 8.62
Av. Daily Volume 50,997

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 failed to meet endpoint - July 2016
Phase 2 enrollment to be completed in mid-2017.
Namodenoson (CF102)
Cancer - advanced liver cancer second line
Phase 3 to be initiated in 2017.
Rheumatoid arthritis
Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 planned for 2H 2017.
Phase 2 to be initiated 1Q 2017.
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Can-Fite Receives IRB Approval to Commence Patient Enrollment in Phase II NAFLD/NASH Trial in Q1 2017
  2. Can-Fite Receives $500,000 Payment as Part of $3 Million Distribution Deal for Liver Cancer Drug Namodenoson (CF102) in South Korea
  3. New Preclinical Data Show Can-Fite's Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy in Treatment of NASH
  4. Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update
  5. American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102
  6. Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
  7. Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany
  8. Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA
  9. Can-Fite Signs Distribution Deal for Liver Cancer Drug CF102 in South Korea
  10. Can-Fite Submits Protocol for NAFLD/NASH CF102 Drug (CANF)
  11. Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
  12. Positive Data on Liver Cancer Drug (CANF)
  13. Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
  14. Can-Fite Secures Patent for Psoriasis Treatment
  15. Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial
  16. Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016
  17. Can-Fite Reports Financial Results for Six Months Ended June 30, 2016
  18. Can-Fite (CANF): Update on its Clinical Programs
  19. Can-Fite's Phase II/III Psoriasis Study Results Published in Journal of Drugs in Dermatology
  20. Can-Fite Completes Phase II Study Design for CF102 in the Treatment of NASH/NAFLD